Managing emerging mutagenicity risks: Late stage mutagenic impurity control within the atovaquone second generation...

Area of Science:

• Pharmaceutical Chemistry
• Process Chemistry
• Analytical Chemistry

Background:

• Developing safe and effective pharmaceutical manufacturing processes is critical.
• Controlling mutagenic impurities is a key regulatory requirement.
• Atovaquone is an important antipneumocystic agent.

Purpose of the Study:

• To describe a control strategy for mutagenic impurities in a second-generation atovaquone manufacturing route.
• To demonstrate the effectiveness of process purging for impurity removal.
• To justify an ICH M7 Option 4 approach for impurity control.

Main Methods:

• Preliminary assessment of potential impurities.
• Genotoxicity testing.
• Process purging studies, including spiking and recovery experiments.
• Development of 1H NMR spectroscopy methods for impurity quantification.
• ICH M7 guideline application.

Main Results:

• Multiple potential impurities were identified and largely discharged through assays or process purging.
• Two specific impurities required further investigation, initially suggesting trace-level testing.
• Process understanding and experimental data justified an ICH M7 Option 4 control strategy.
• 1H NMR methods were developed for impurity measurement.

Conclusions:

• Process purging can effectively control mutagenic impurities, even when introduced late in synthesis.
• Scientific understanding of process parameters and purging is crucial for impurity control.
• An ICH M7 Option 4 approach can be justified through robust process data.
• This strategy reduces reliance on simple stage-counting for impurity management.